Tandem Diabetes Care Financials - Benzinga

Tandem Diabetes Care Inc

TNDMNASDAQ

Trade with Public

Trade with Public

$15.72

0.503.29%

al cierre: Sep 25, 5:00 PM EST

$16.06

0.342.16%

After hour: Sep 25, 7:11 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Tandem Diabetes Care Financials

Tandem Diabetes Care (TNDM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Tandem Diabetes Care Q2 EPS $(0.31) Beats $(0.32) Estimate, Sales $254.560M Miss $254.978M Estimate

Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 60.26 percent increase over losses of $(0.78) per share

Benzinga Newsdesk

PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est

Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.

Benzinga Newsdesk

PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.076B Est.

Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.076 billion estimate.

Benzinga Newsdesk

PRO
Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate.

Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 54.55 percent increase over losses of $(0.67) per share

Benzinga Newsdesk

Dow Jumps Over 200 Points After Court's Tariff Ruling: Investor Sentiment Improves, Greed Index Remains In 'Fear' Zone

U.S. stocks rise after Supreme Court decision on tariffs. Fear & Greed index eases but remains in 'Fear' zone.

Avi Kapoor

Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook

Tandem Diabetes stock surges after earnings beat and margin growth, as investors weigh 2026 sales guidance and market momentum.

Vandana Singh

© 2026 Benzinga | All Rights Reserved